The invention relates to brartemicin analogues of Formula IV and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.

##STR00001##

The invention relates to brartemicin analogues of Formula IV and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.

##STR00001##

Infant formulas that include a combination of RRR-alpha-tocopherol, 2′-fucosyllactose, and at least one probiotic from the Lactobacillus or the Bifidobacterium genera are disclosed. Also provided are methods of use of the infant formulas for improving at least one of cognition, learning, and memory in an infant. The methods include administering the infant formulas to an infant.

Infant formulas that include a combination of RRR-alpha-tocopherol, 2′-fucosyllactose, and at least one probiotic from the Lactobacillus or the Bifidobacterium genera are disclosed. Also provided are methods of use of the infant formulas for improving at least one of cognition, learning, and memory in an infant. The methods include administering the infant formulas to an infant.

A water-insoluble composition, solid in appearance at a temperature of less than or equal to 20° C., comprising, for 100% of the mass of same:—X1% by mass of at least one lipophilic surfactant having a value HLB, H1, greater than or equal to 1 and less than 10;—X2% by mass of at least one hydrophilic surfactant having a value HLB, H2, greater than or equal to 10 and less than or equal to 20; characterised by the fact that the HLB of same=X1.H1+X2.H2, X1 and X2 varying from 2 to 60, and characterised in that it is free of acrylic polymer and/or of acetate succinate.

A water-insoluble composition, solid in appearance at a temperature of less than or equal to 20° C., comprising, for 100% of the mass of same:—X1% by mass of at least one lipophilic surfactant having a value HLB, H1, greater than or equal to 1 and less than 10;—X2% by mass of at least one hydrophilic surfactant having a value HLB, H2, greater than or equal to 10 and less than or equal to 20; characterised by the fact that the HLB of same=X1.H1+X2.H2, X1 and X2 varying from 2 to 60, and characterised in that it is free of acrylic polymer and/or of acetate succinate.

Crystalline difucosyllactose, useful in a pharmaceutical composition and a nutritional composition, is disclosed.

Described herein are functionalizing nanocomplexes comprising one or more polyphenol molecules; and one or more biomolecules. Further described herein are functionalized cells comprising one or more of the nanocomplexes. In some embodiments, the biomolecules can be therapeutic agents and the functionalized cells can be administered to patients to provide improved delivery (e.g., dosing and specificity) of the therapeutic agent.

Disclosed aspects include characterizing of the metabolite secretome of apoptotic cells, deciphering metabolite-based communication between dying cells and neighboring live cells, and harnessing components of the secretome for beneficial effects in vivo. In representative embodiments, a composition comprising, consisting essentially of, or consisting of an effective amount of a plurality of metabolite compounds derived from an apoptotic cell is disclosed, as are methods of treating an inflammatory condition in a subject and modulating gene expression in a subject using the composition.

Disclosed aspects include characterizing of the metabolite secretome of apoptotic cells, deciphering metabolite-based communication between dying cells and neighboring live cells, and harnessing components of the secretome for beneficial effects in vivo. In representative embodiments, a composition comprising, consisting essentially of, or consisting of an effective amount of a plurality of metabolite compounds derived from an apoptotic cell is disclosed, as are methods of treating an inflammatory condition in a subject and modulating gene expression in a subject using the composition.